Immuno-based therapeutic strategies for initial unresectable locally advanced non-small cell lung cancer: a case report

Lung cancer is the leading global cause of cancer-related deaths. Even for patients who receive multidimensional treatment, the prognosis for locally advanced lung cancer is poor. The outcomes of neoadjuvant immunotherapy have been encouraging in many types of cancer, and especially lung cancer. However, the prognoses of patients with initially unresectable non-small cell lung cancer (NSCLC) with T4 or bulky swollen N2 lymph nodes are still unsatisfying, and novel therapeutic modalities are desperately needed. Here, we present a case of a patient with initially unresectable NSCLC with T4 and bulky swollen N2 lymph nodes, and present the argument for neoadjuvant immuno-based therapeutic strategies as a reasonable option for such patients.